July 26, 2019 06:23 AM EDT
Deals

Boston's Neu­roBo to use bruised Gem­phire to make Nas­daq de­but

Natalie Grover

Reporter

A bat­tered Gem­phire will be put out of its mis­ery by Boston-based biotech Neu­roBo Phar­ma­ceu­ti­cals, which is re­verse merg­ing with the Michi­gan drug de­vel­op­er to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times